Uni-Bio Science Group Limited
Research Uni-Bio Science Group Limited (0690.HK) on Bullrun: market cap HKD 400.07M, P/E 6.7, dividend yield 4.7%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker0690.HK
- ExchangeHK
- CountryHong Kong
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 400.07M
- P/E6.7
- Dividend yield4.7%
- Financial periodFY2025
- RevenueHKD 586.21M
- Revenue growth6.0%
- Net incomeHKD 93.33M
- Free cash flowHKD 36.56M
- Gross margin83.2%
Valuation Snapshot
latest market cap is HKD 400.07M; P/E is 6.7; dividend yield is 4.7%.
Peer valuation comparison
Latest P/E is 6.7x versus a Healthcare sector median of 21.75x (69.2% below).
Latest dividend yield is 4.67% versus a Healthcare sector median of 2.4% (94.6% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | HKD 586.21M | HKD 93.33M | HKD 36.56M | 83.2% | 0.02 | HKD 168.82M | HKD 97.76M | HKD 413.25M |
| FY2024 | HKD 552.98M | HKD 82.77M | HKD 28.71M | 83.4% | 0.01 | HKD 54.21M | HKD 115.19M | HKD 325.65M |
| FY2023 | HKD 484.72M | HKD 70.88M | HKD 39.11M | 81.0% | 0.01 | HKD 129.24M | HKD 56.30M | HKD 257.17M |
| FY2022 | HKD 440.32M | HKD 38.51M | HKD 20.23M | 76.1% | 0.01 | HKD 98.22M | HKD 22.67M | HKD 194.75M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 400.07M | 6.7 | 4.7% | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD, yield 4.7%.
| Year | Dividends/share |
|---|---|
| FY2025 | 0 HKD |
About Uni-Bio Science Group Limited
Uni-Bio Science Group Limited, an investment holding company, researches and develops, manufactures, and sells biological and chemical pharmaceutical products to treat human diseases in Hong Kong, and People's Republic of China. It operates through Chemical Pharmaceutical Products, Biological Pharmaceutical Products, and Pipeline Products segments. The company provides BOGUTAI, a disposable injection pen for the treatment of osteoporosis; GeneTime, a prescription biological drug for wound healing;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Uni-Bio Science Group Limited's market cap?
Uni-Bio Science Group Limited's market capitalization is HKD 400.07M.
What is Uni-Bio Science Group Limited's P/E ratio?
Uni-Bio Science Group Limited's price-to-earnings (P/E) ratio is 6.7.
Does Uni-Bio Science Group Limited pay a dividend?
Uni-Bio Science Group Limited has a dividend yield of 4.7%.
What does Uni-Bio Science Group Limited do?
Uni-Bio Science Group Limited, an investment holding company, researches and develops, manufactures, and sells biological and chemical pharmaceutical products to treat human diseases in Hong Kong, and People's Republic of China. It operates through Chemical Pharmaceutical Products, Biological Pharmaceutical Products, and Pipeline Products segments.